Zhaoyi Zhao

Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 2   
Received: 22 Apr., 2024    Accepted: 29 Apr., 2024    Published: 03 May, 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The paper "Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC), published in The Lancet on April 20, 2024: a randomised, placebo-controlled trial", Written by Michael J. Foley, Christopher A. Rajkumar, F. Ahmed-Jushuf, et al. From Imperial College London, Midlands and South Essex NHS Foundation Trust, Anglia Ruskin University, etc. In this study, the researchers investigated the effects of coronary sinus reducers (CSR) in the treatment of refractory angina pectoris through the ORBITA-COSMIC trial. The study was conducted in six UK hospitals using a double-blind, randomized, placebo-controlled approach to assess the effectiveness of CSR compared to placebo in improving myocardial ischemia and angina symptoms. The study was conducted in patients over 18 years of age with stable coronary artery disease and myocardial ischemia who had no other treatment options. The results of the study showed that although the effect of CSR in improving myocardial blood flow was not significant, it had a significant effect compared to placebo in reducing the frequency of angina attacks. These findings provide a scientific basis for CSR as a new treatment option against angina pectoris.

Coronary sinus downsizing; Angina; Treatment; ORBITA-COSMIC